Results 231 to 240 of about 115,578 (309)

Retraction: Design, synthesis, and quorum quenching potential of novel catechol-zingerone conjugate to find an elixir to tackle <i>Pseudomonas aeruginosa</i> through the trojan horse strategy. [PDF]

Front Chem
Frontiers Editorial Office.
europepmc   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Positron Emission Tomography Imaging of Bacterial Infections With an Enterobactin Analog to Monitor Treatment Efficacy With a Catechol Antibiotic. [PDF]

Angew Chem Int Ed Engl
Joaqui-Joaqui MA, Tran PN, Marlin A, Armstrong-Pavlik F, Cao M, Pierre VC, Boros E.   +6 more
europepmc   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease

Neuroprotection, EarlyView.
In Parkinson's disease (PD) and Alzheimer's disease (AD), various shared pathological mechanisms exist. UDCA has been shown to exert neuroprotective effects in preclinical and clinical studies. Such effects include the mitigation of neuroinflammation as well as rescue effects on mitochondrial dysfunction, oxidative stress, impaired autophagy, and ...
Ashley En Yi Chong, Andrew Octavian Sasmita, Rhun Yian Koh, Anna Pick Kiong Ling   +3 more
wiley   +1 more source

Mechanistic insights into efficient catechol removal using saponin-based emulsion liquid membrane. [PDF]

Sci Rep
Wakle M, Khuntia S.
europepmc   +1 more source

Fendioxypyracil, a new and systemic PPO‐inhibiting herbicide for X‐spectrum weed control

Pest Management Science, EarlyView.
This graphical abstract presents the discovery and synthesis of PPO herbicide structures with a central pyridine core, showing molecular conformations, dose–response inhibition curves for PPO1 and PPO2, and comparative weed and grass control efficacy of fendioxypyracil versus other herbicides in greenhouse and field trials.
Tobias Seiser, Aimone Porri, Philipp Johnen, Silke Zeyer, Judith Wahrheit, Michael Betz, Breght Vandenberghe, Scott Asher, Liliana Parra Rapado   +8 more
wiley   +1 more source

Catechol Tetrahydroisoquinolines: Synthesis, Biological Activity, and Natural Occurrence in <i>Portulaca oleracea</i> as Analyzed by UPLC-Q-TOF-ESI-MS/MS. [PDF]

ACS Omega
Wang AY, Gu SB, Ji XQ, Bai HB, Liu CY, Guo QF, Xu ZP, Zhao Y, Shen T, Xiang L.   +9 more
europepmc   +1 more source

Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies–A Systematic Review

Phytotherapy Research, EarlyView.
Overview of the therapeutic potential of flavonoids in nasal delivery systems, highlighting their benefits to the human nasal cavity, and applications in the treatment of respiratory and brain‐related diseases. ABSTRACT Flavonoids represent a significant group of secondary metabolites.
Jeniffer Viviana Ramirez Hernández, Sara Elis Bianchi, Flávia Nathiely Silveira Fachel, Elizandra Braganhol, Sheila Porto de Matos, Valquíria Linck Bassani   +5 more
wiley   +1 more source